

# **BONN GUIDELINES ON ACCESS TO GENETIC RESOURCES AND FAIR AND EQUITABLE SHARING OF THE BENEFITS ARISING OUT OF THEIR UTILIZATION**

## **I. GENERAL PROVISIONS**

### **A. Key features**

1. These Guidelines may serve as inputs when developing and drafting legislative, administrative or policy measures on access and benefit-sharing with particular reference to provisions under Articles 8(j), 10 (c), 15, 16 and 19; and contracts and other arrangements under mutually agreed terms for access and benefit-sharing.
2. Nothing in these Guidelines shall be construed as changing the rights and obligations of Parties under the Convention on Biological Diversity.
3. Nothing in these Guidelines is intended to substitute for relevant national legislation.
4. Nothing in these Guidelines should be interpreted to affect the sovereign rights of States over their natural resources;
5. Nothing in these Guidelines, including the use of terms such as "provider", "user", and "stakeholder", should be interpreted to assign any rights over genetic resources beyond those provided in accordance with the Convention;
6. Nothing in these Guidelines should be interpreted as affecting the rights and obligations relating to genetic resources arising out of the mutually agreed terms under which the resources were obtained from the country of origin.
7. The present Guidelines are voluntary and were prepared with a view to ensuring their:
  - a. Voluntary nature: they are intended to guide both users and providers of genetic resources on a voluntary basis;
  - b. Ease of use: to maximize their utility and to accommodate a range of applications, the Guidelines are simple;
  - c. Practicality: the elements contained in the guidelines are practical and are aimed at reducing transaction costs;
  - d. Acceptability: the Guidelines are intended to gain the support of users and providers;
  - e. Complementarity: the Guidelines and other international instruments are mutually supportive;
  - f. Evolutionary approach: the Guidelines are intended to be reviewed and accordingly revised and improved as experience is gained in access and benefit-sharing;
  - g. Flexibility: to be useful across a range of sectors, users and national circumstances and jurisdictions, guidelines should be flexible;
  - h. Transparency: they are intended to promote transparency in the negotiation and implementation of access and benefit-sharing arrangements.

### **B. Use of terms**

8. The terms as defined in Article 2 of the Convention shall apply to these Guidelines. These include: biological diversity, biological resources, biotechnology, country of

origin of genetic resources, country providing genetic resources, *ex situ* conservation, in situ conservation, genetic material, genetic resources, and in situ conditions.

### **C. Scope**

9. All genetic resources and associated traditional knowledge, innovations and practices covered by the Convention on Biological Diversity and benefits arising from the commercial and other utilization of such resources should be covered by the guidelines, with the exclusion of human genetic resources.

### **D. Relationship with relevant international regimes**

10. The guidelines should be applied in a manner that is coherent and mutually supportive of the work of relevant international agreements and institutions. The guidelines are without prejudice to the access and benefit-sharing provisions of the FAO International Treaty for Plant Genetic Resources for Food and Agriculture. Furthermore, the work of the World Intellectual Property Organization (WIPO) on issues of relevance to access and benefit-sharing should be taken into account. The application of the guidelines should also take into account existing regional legislation and agreements on access and benefit-sharing.

### **E. Objectives**

11. The objectives of the Guidelines are the following:
  - a. To contribute to the conservation and sustainable use of biological diversity;
  - b. To provide Parties and stakeholders with a transparent framework to facilitate access to genetic resources and ensure fair and equitable sharing of benefits;
  - c. To provide guidance to Parties in the development of access and benefit-sharing regimes;
  - d. To inform the practices and approaches of stakeholders (users and providers) in access and benefit-sharing arrangements;
  - e. To provide capacity-building to guarantee the effective negotiation and implementation of access and benefit-sharing arrangements, especially to developing countries, in particular least developed countries and small island developing States among them;
  - f. To promote awareness on implementation of relevant provisions of the Convention on Biological Diversity;
  - g. To promote the adequate and effective transfer of appropriate technology to providing Parties, especially developing countries, in particular least developed countries and small island developing States among them, stakeholders and indigenous and local communities;
  - h. To promote the provision of necessary financial resources to providing countries that are developing countries, in particular least developed countries and small island developing States among them, or countries with economies in transition with a view to contributing to the achievement of the objectives mentioned above;
  - i. To strengthen the clearing-house mechanism as a mechanism for cooperation among Parties in access and benefit-sharing;
  - j. To contribute to the development by Parties of mechanisms and access and benefit-sharing regimes that recognize the protection of traditional knowledge,

innovations and practices of indigenous and local communities, in accordance with domestic laws and relevant international instruments;

- k. To contribute to poverty alleviation and be supportive to the realization of human food security, health and cultural integrity, especially in developing countries, in particular least developed countries and small island developing States among them;
  - l. Taxonomic research, as specified in the Global Taxonomy Initiative, should not be prevented, and providers should facilitate acquisition of material for systematic use and users should make available all information associated with the specimens thus obtained.
12. The Guidelines are intended to assist Parties in developing an overall access and benefit-sharing strategy, which may be part of their national biodiversity strategy and action plan, and in identifying the steps involved in the process of obtaining access to genetic resources and sharing benefits.

## **II. ROLES AND RESPONSIBILITIES IN ACCESS AND BENEFIT-SHARING PURSUANT TO ARTICLE 15 OF THE CONVENTION ON BIOLOGICAL DIVERSITY**

### **A. National focal point**

13. Each Party should designate one national focal point for access and benefit-sharing and make such information available through the clearing-house mechanism. The national focal point should inform applicants for access to genetic resources on procedures for acquiring prior informed consent and mutually agreed terms, including benefit-sharing, and on competent national authorities, relevant indigenous and local communities and relevant stakeholders, through the clearing-house mechanism.

### **B. Competent national authority(ies)**

14. Competent national authorities, where they are established, may, in accordance with applicable national legislative, administrative or policy measures, be responsible for granting access and be responsible for advising on:
- a. The negotiating process;
  - b. Requirements for obtaining prior informed consent and entering into mutually agreed terms;
  - c. Monitoring and evaluation of access and benefit-sharing agreements;
  - d. Implementation/enforcement of access and benefit-sharing agreements;
  - e. Processing of applications and approval of agreements;
  - f. The conservation and sustainable use of the genetic resources accessed;
  - g. Mechanisms for the effective participation of different stakeholders, as appropriate for the different steps in the process of access and benefit-sharing, in particular, indigenous and local communities;
  - h. Mechanisms for the effective participation of indigenous and local communities while promoting the objective of having decisions and processes available in a language understandable to relevant indigenous and local communities.
15. The competent national authority(ies) that have the legal power to grant prior informed consent may delegate this power to other entities, as appropriate.

### **C. Responsibilities**

16. Recognizing that Parties and stakeholders may be both users and providers, the following balanced list of roles and responsibilities provides key elements to be acted upon:
- a. Contracting Parties which are countries of origin of genetic resources, or other Parties which have acquired the genetic resources in accordance with the Convention, should:
    - i. Be encouraged to review their policy, administrative and legislative measures to ensure they are fully complying with Article 15 of the Convention;
    - ii. Be encouraged to report on access applications through the clearing-house mechanism and other reporting channels of the Convention;
    - iii. Seek to ensure that the commercialization and any other use of genetic resources should not prevent traditional use of genetic resources;
    - iv. Ensure that they fulfil their roles and responsibilities in a clear, objective and transparent manner;
    - v. Ensure that all stakeholders take into consideration the environmental consequences of the access activities;
    - vi. Establish mechanisms to ensure that their decisions are made available to relevant indigenous and local communities and relevant stakeholders, particularly indigenous and local communities;
    - vii. Support measures, as appropriate, to enhance indigenous and local communities' capacity to represent their interests fully at negotiations;
  - b. In the implementation of mutually agreed terms, users should:
    - i. Seek informed consent prior to access to genetic resources, in conformity with Article 15, paragraph 5, of the Convention;
    - ii. Respect customs, traditions, values and customary practices of indigenous and local communities,
    - iii. Respond to requests for information from indigenous and local communities;
    - iv. Only use genetic resources for purposes consistent with the terms and conditions under which they were acquired;
    - v. Ensure that uses of genetic resources for purposes other than those for which they were acquired, only take place after new prior informed consent and mutually agreed terms are given;
    - vi. Maintain all relevant data regarding the genetic resources, especially documentary evidence of the prior informed consent and information concerning the origin and the use of genetic resources and the benefits arising from such use;
    - vii. As much as possible endeavour to carry out their use of the genetic resources in, and with the participation of, the providing country;

- viii. When supplying genetic resources to third parties, honour any terms and conditions regarding the acquired material. They should provide this third party with relevant data on their acquisition, including prior informed consent and conditions of use and record and maintain data on their supply to third parties. Special terms and conditions should be established under mutually agreed terms to facilitate taxonomic research for non-commercial purposes;
  - ix. Ensure the fair and equitable sharing of benefits, including technology transfer to providing countries, pursuant to Article 16 of the Convention arising from the commercialization or other use of genetic resources, in conformity with the mutually agreed terms they established with the indigenous and local communities or stakeholders involved;
- c. Providers should:
- i. Only supply genetic resources and/or traditional knowledge when they are entitled to do so;
  - ii. Strive to avoid imposition of arbitrary restrictions on access to genetic resources.
- d. Contracting Parties with users of genetic resources under their jurisdiction should take appropriate legal, administrative, or policy measures, as appropriate, to support compliance with prior informed consent of the Contracting Party providing such resources and mutually agreed terms on which access was granted. These countries could consider, *inter alia*, the following measures:
- i. Mechanisms to provide information to potential users on their obligations regarding access to genetic resources;
  - ii. Measures to encourage the disclosure of the country of origin of the genetic resources and of the origin of traditional knowledge, innovations and practices of indigenous and local communities in applications for intellectual property rights;
  - iii. Measures aimed at preventing the use of genetic resources obtained without the prior informed consent of the Contracting Party providing such resources;
  - iv. Cooperation between Contracting Parties to address alleged infringements of access and benefit-sharing agreements;
  - v. Voluntary certification schemes for institutions abiding by rules on access and benefit-sharing;
  - vi. Measures discouraging unfair trade practices;
  - vii. Other measures that encourage users to comply with provisions under subparagraph ?16 (b) above.

### **III. PARTICIPATION OF STAKEHOLDERS**

17. Involvement of relevant stakeholders is essential to ensure the adequate development and implementation of access and benefit-sharing arrangements. However, due to the diversity of stakeholders and their diverging interests, their appropriate involvement can only be determined on a case-by-case basis.

18. Relevant stakeholders should be consulted and their views taken into consideration in each step of the process, including:
  - a. When determining access, negotiating and implementing mutually agreed terms, and in the sharing of benefits;
  - b. In the development of a national strategy, policies or regimes on access and benefit-sharing.
19. To facilitate the involvement of relevant stakeholders, including indigenous and local communities, appropriate consultative arrangements, such as national consultative committees, comprising relevant stakeholder representatives, should be made.
20. The involvement of relevant stakeholders should be promoted by:
  - a. Providing information, especially regarding scientific and legal advice, in order for them to be able to participate effectively;
  - b. Providing support for capacity-building, in order for them to be actively engaged in various stages of access and benefit-sharing arrangements, such as in the development and implementation of mutually agreed terms and contractual arrangements.
21. The stakeholders involved in access to genetic resources and benefit-sharing may wish to seek the support of a mediator or facilitator when negotiating mutually agreed terms.

#### **IV. STEPS IN THE ACCESS AND BENEFIT-SHARING PROCESS**

##### **A. Overall strategy**

22. Access and benefit-sharing systems should be based on an overall access and benefit-sharing strategy at the country or regional level. This access and benefit-sharing strategy should aim at the conservation and sustainable use of biological diversity, and may be part of a national biodiversity strategy and action plan and promote the equitable sharing of benefits.

##### **B. Identification of steps**

23. The steps involved in the process of obtaining access to genetic resources and sharing of benefits may include activities prior to access, research and development conducted on the genetic resources, as well as their commercialization and other uses, including benefit-sharing.

##### **C. Prior informed consent**

24. As provided for in Article 15 of the Convention on Biological Diversity, which recognizes the sovereign rights of States over their natural resources, each Contracting Party to the Convention shall endeavour to create conditions to facilitate access to genetic resources for environmentally sound uses by other Contracting Parties and fair and equitable sharing of benefits arising from such uses. In accordance with Article 15, paragraph 5, of the Convention on Biological Diversity, access to genetic resources shall be subject to prior informed consent of the contracting Party providing such resources, unless otherwise determined by that Party.
25. Against this background, the Guidelines are intended to assist Parties in the establishment of a system of prior informed consent, in accordance with Article 15, paragraph 5, of the Convention.

##### **1. Basic principles of a prior informed consent system**

26. The basic principles of a prior informed consent system should include:
- a. Legal certainty and clarity;
  - b. Access to genetic resources should be facilitated at minimum cost;
  - c. Restrictions on access to genetic resources should be transparent, based on legal grounds, and not run counter to the objectives of the Convention;
  - d. Consent of the relevant competent national authority(ies) in the provider country. The consent of relevant stakeholders, such as indigenous and local communities, as appropriate to the circumstances and subject to domestic law, should also be obtained.

## **2. Elements of a prior informed consent system**

27. Elements of a prior informed consent system may include:
- a. Competent authority(ies) granting or providing for evidence of prior informed consent;
  - b. Timing and deadlines;
  - c. Specification of use;
  - d. Procedures for obtaining prior informed consent;
  - e. Mechanism for consultation of relevant stakeholders;
  - f. Process.

### **Competent authority(ies) granting prior informed consent**

28. Prior informed consent for access to in situ genetic resources shall be obtained from the Contracting Party providing such resources, through its competent national authority(ies), unless otherwise determined by that Party.
29. In accordance with national legislation, prior informed consent may be required from different levels of Government. Requirements for obtaining prior informed consent (national/provincial/local) in the provider country should therefore be specified.
30. National procedures should facilitate the involvement of all relevant stakeholders from the community to the government level, aiming at simplicity and clarity.
31. Respecting established legal rights of indigenous and local communities associated with the genetic resources being accessed or where traditional knowledge associated with these genetic resources is being accessed, the prior informed consent of indigenous and local communities and the approval and involvement of the holders of traditional knowledge, innovations and practices should be obtained, in accordance with their traditional practices, national access policies and subject to domestic laws.
32. For *ex situ* collections, prior informed consent should be obtained from the competent national authority(ies) and/or the body governing the *ex situ* collection concerned as appropriate.

### **Timing and deadlines**

33. Prior informed consent is to be sought adequately in advance to be meaningful both for those seeking and for those granting access. Decisions on applications for access to genetic resources should also be taken within a reasonable period of time.

### **Specification of use**

34. Prior informed consent should be based on the specific uses for which consent has been granted. While prior informed consent may be granted initially for specific use(s), any change of use including transfer to third parties may require a new application for prior informed consent. Permitted uses should be clearly stipulated and further prior informed consent for changes or unforeseen uses should be required. Specific needs of taxonomic and systematic research as specified by the Global Taxonomy Initiative should be taken into consideration.
35. Prior informed consent is linked to the requirement of mutually agreed terms.

### **Procedures for obtaining prior informed consent**

36. An application for access could require the following information to be provided, in order for the competent authority to determine whether or not access to a genetic resource should be granted. This list is indicative and should be adapted to national circumstances:
  - a. Legal entity and affiliation of the applicant and/or collector and contact person when the applicant is an institution;
  - b. Type and quantity of genetic resources to which access is sought;
  - c. Starting date and duration of the activity;
  - d. Geographical prospecting area;
  - e. Evaluation of how the access activity may impact on conservation and sustainable use of biodiversity, to determine the relative costs and benefits of granting access;
  - f. Accurate information regarding intended use (e.g.: taxonomy, collection, research, commercialization);
  - g. Identification of where the research and development will take place;
  - h. Information on how the research and development is to be carried out;
  - i. Identification of local bodies for collaboration in research and development;
  - j. Possible third party involvement;
  - k. Purpose of the collection, research and expected results;
  - l. Kinds/types of benefits that could come from obtaining access to the resource, including benefits from derivatives and products arising from the commercial and other utilization of the genetic resource;
  - m. Indication of benefit-sharing arrangements;
  - n. Budget;
  - o. Treatment of confidential information.
37. Permission to access genetic resources does not necessarily imply permission to use associated knowledge and vice versa.



## **Process**

38. Applications for access to genetic resources through prior informed consent and decisions by the competent authority(ies) to grant access to genetic resources or not shall be documented in written form.
39. The competent authority could grant access by issuing a permit or licence or following other appropriate procedures. A national registration system could be used to record the issuance of all permits or licences, on the basis of duly completed application forms.
40. The procedures for obtaining an access permit/licence should be transparent and accessible by any interested party.

## **D. Mutually agreed terms**

41. In accordance with Article 15, paragraph 7, of the Convention on Biological Diversity, each Contracting Party shall "take legislative, administrative or policy measures, as appropriate (...) with the aim of sharing in a fair and equitable way the results of research and development and the benefits arising from the commercial and other utilization of genetic resources with the Contracting Party providing such resources. Such sharing shall be upon mutually agreed terms". Thus, guidelines should assist Parties and stakeholders in the development of mutually agreed terms to ensure the fair and equitable sharing of benefits.

### **1. Basic requirements for mutually agreed terms**

42. The following principles or basic requirements could be considered for the development of mutually agreed terms:
  - a. Legal certainty and clarity;
  - b. Minimization of transaction costs, by, for example:
    - i. Establishing and promoting awareness of the Government's and relevant stakeholders' requirements for prior informed consent and contractual arrangements;
    - ii. Ensuring awareness of existing mechanisms for applying for access, entering into arrangements and ensuring the sharing of benefits;
    - iii. Developing framework agreements, under which repeat access under expedited arrangements can be made;
    - iv. Developing standardized material transfer agreements and benefit-sharing arrangements for similar resources and similar uses (see appendix I for suggested elements of such an agreement);
  - c. Inclusion of provisions on user and provider obligations;
  - d. Development of different contractual arrangements for different resources and for different uses and development of model agreements;
  - e. Different uses may include, *inter alia*, taxonomy, collection, research, commercialization;
  - f. Mutually agreed terms should be negotiated efficiently and within a reasonable period of time;
  - g. Mutually agreed terms should be set out in a written agreement.

43. The following elements could be considered as guiding parameters in contractual agreements. These elements could also be considered as basic requirements for mutually agreed terms:
- a. Regulating the use of resources in order to take into account ethical concerns of the particular Parties and stakeholders, in particular indigenous and local communities concerned;
  - b. Making provision to ensure the continued customary use of genetic resources and related knowledge;
  - c. Provision for the use of intellectual property rights include joint research, obligation to implement rights on inventions obtained and to provide licences by common consent;
  - d. The possibility of joint ownership of intellectual property rights according to the degree of contribution.

## **2. Indicative list of typical mutually agreed terms**

44. The following provides an indicative list of typical mutually agreed terms:
- a. Type and quantity of genetic resources, and the geographical/ecological area of activity;
  - b. Any limitations on the possible use of the material;
  - c. Recognition of the sovereign rights of the country of origin;
  - d. Capacity-building in various areas to be identified in the agreement;
  - e. A clause on whether the terms of the agreement in certain circumstances (e.g. change of use) can be renegotiated;
  - f. Whether the genetic resources can be transferred to third parties and conditions to be imposed in such cases, e.g. whether or not to pass genetic resources to third parties without ensuring that the third parties enter into similar agreements except for taxonomic and systematic research that is not related to commercialization;
  - g. Whether the knowledge, innovations and practices of indigenous and local communities have been respected, preserved and maintained, and whether the customary use of biological resources in accordance with traditional practices has been protected and encouraged;
  - h. Treatment of confidential information;
  - i. Provisions regarding the sharing of benefits arising from the commercial and other utilization of genetic resources and their derivatives and products .

## **3. Benefit-sharing**

45. Mutually agreed terms could cover the conditions, obligations, procedures, types, timing, distribution and mechanisms of benefits to be shared. These will vary depending on what is regarded as fair and equitable in light of the circumstances.

### **Types of benefits**

46. Examples of monetary and non-monetary benefits are provided in appendix II to these Guidelines.

### **Timing of benefits**

47. Near-term, medium-term and long-term benefits should be considered, including up-front payments, milestone payments and royalties. The time-frame of benefit-sharing should be definitely stipulated. Furthermore, the balance among near-term, medium-term and long-term benefit should be considered on a case-by-case basis.

### **Distribution of benefits**

48. Pursuant to mutually agreed terms established following prior informed consent, benefits should be shared fairly and equitably with all those who have been identified as having contributed to the resource management, scientific and/or commercial process. The latter may include governmental, non-governmental or academic institutions and indigenous and local communities. Benefits should be directed in such a way as to promote conservation and sustainable use of biological diversity.

### **Mechanisms for benefit-sharing**

49. Mechanisms for benefit-sharing may vary depending upon the type of benefits, the specific conditions in the country and the stakeholders involved. The benefit-sharing mechanism should be flexible as it should be determined by the partners involved in benefit-sharing and will vary on a case-by-case basis.
50. Mechanisms for sharing benefits should include full cooperation in scientific research and technology development, as well as those that derive from commercial products including trust funds, joint ventures and licences with preferential terms.

## **V. OTHER PROVISIONS**

### **A. Incentives**

51. The following incentive measures exemplify measures which could be used in the implementation of the guidelines:
  - a. The identification and mitigation or removal of perverse incentives, that may act as obstacles for conservation and sustainable use of biological diversity through access and benefit-sharing, should be considered;
  - b. The use of well-designed economic and regulatory instruments, directly or indirectly related to access and benefit-sharing, should be considered to foster equitable and efficient allocation of benefits;
  - c. The use of valuation methods should be considered as a tool to inform users and providers involved in access and benefit-sharing;
  - d. The creation and use of markets should be considered as a way of efficiently achieving conservation and sustainable use of biological diversity.

### **B. Accountability in implementing access and benefit-sharing arrangements**

52. Parties should endeavour to establish mechanisms to promote accountability by all stakeholders involved in access and benefit-sharing arrangements.
53. To promote accountability, Parties may consider establishing requirements regarding:
  - a. Reporting; and
  - b. Disclosure of information.

54. The individual collector or institution on whose behalf the collector is operating should, where appropriate, be responsible and accountable for the compliance of the collector.

### **C. National monitoring and reporting**

55. Depending on the terms of access and benefit-sharing, national monitoring may include:
- a. Whether the use of genetic resources is in compliance with the terms of access and benefit-sharing;
  - b. Research and development process;
  - c. Applications for intellectual property rights relating to the material supplied.
56. The involvement of relevant stakeholders, in particular, indigenous and local communities, in the various stages of development and implementation of access and benefit-sharing arrangements can play an important role in facilitating the monitoring of compliance.

### **D. Means for verification**

57. Voluntary verification mechanisms could be developed at the national level to ensure compliance with the access and benefit-sharing provisions of the Convention on Biological Diversity and national legal instruments of the country of origin providing the genetic resources.
58. A system of voluntary certification could serve as a means to verify the transparency of the process of access and benefit-sharing. Such a system could certify that the access and benefit-sharing provisions of the Convention on Biological Diversity have been complied with.

### **E. Settlement of disputes**

59. As most obligations arising under mutually agreed arrangements will be between providers and users, disputes arising in these arrangements should be solved in accordance with the relevant contractual arrangements on access and benefit-sharing and the applicable law and practices.
60. In cases where the access and benefit-sharing agreements consistent with the Convention on Biological Diversity and national legal instruments of the country of origin of genetic resources have not been complied with, the use of sanctions could be considered, such as penalty fees set out in contractual agreements.

### **F. Remedies**

61. Parties may take appropriate effective and proportionate measures for violations of national legislative, administrative or policy measures implementing the access and benefit-sharing provisions of the Convention on Biological Diversity, including requirements related to prior informed consent and mutually agreed terms.

## Appendix I

### **SUGGESTED ELEMENTS FOR MATERIAL TRANSFER AGREEMENTS**

**Material transfer agreements may contain wording on the following elements:**

#### **A. Introductory provisions**

1. Preambular reference to the Convention on Biological Diversity
2. Legal status of the provider and user of genetic resources
3. Mandate and/or general objectives of provider and, where appropriate, user of genetic resources

#### **B. Access and benefit-sharing provisions**

1. Description of genetic resources covered by the material transfer agreements, including accompanying information
2. Permitted uses, bearing in mind the potential uses, of the genetic resources, their products or derivatives under the material transfer agreement (e.g. research, breeding, commercialization)
3. Statement that any change of use would require new prior informed consent and material transfer agreement
4. Whether intellectual property rights may be sought and if so under what conditions
5. Terms of benefit-sharing arrangements, including commitment to share monetary and non-monetary benefits
6. No warranties guaranteed by provider on identity and/or quality of the provided material
7. Whether the genetic resources and/or accompanying information may be transferred to third parties and if so conditions that should apply
8. Definitions
9. Duty to minimize environmental impacts of collecting activities

#### **C. Legal provisions**

1. Obligation to comply with the material transfer agreement
2. Duration of agreement
3. Notice to terminate the agreement
4. Fact that the obligations in certain clauses survive the termination of the agreement
5. Independent enforceability of individual clauses in the agreement
6. Events limiting the liability of either party (such as act of God, fire, flood, etc.)
7. Dispute settlement arrangements
8. Assignment or transfer of rights

9. Assignment, transfer or exclusion of the right to claim any property rights, including intellectual property rights, over the genetic resources received through the material transfer agreement
10. Choice of law
11. Confidentiality clause
12. Guarantee

## Appendix II

### **MONETARY AND NON- MONETARY BENEFITS**

#### **1. Monetary benefits may include, but not be limited to:**

- a. Access fees/fee per sample collected or otherwise acquired;
- b. Up-front payments;
- c. Milestone payments;
- d. Payment of royalties;
- e. Licence fees in case of commercialization;
- f. Special fees to be paid to trust funds supporting conservation and sustainable use of biodiversity;
- g. Salaries and preferential terms where mutually agreed;
- h. Research funding;
- i. Joint ventures;
- j. Joint ownership of relevant intellectual property rights.

#### **2. Non-monetary benefits may include, but not be limited to:**

- a. Sharing of research and development results;
- b. Collaboration, cooperation and contribution in scientific research and development programmes, particularly biotechnological research activities, where possible in the provider country;
- c. Participation in product development;
- d. Collaboration, cooperation and contribution in education and training;
- e. Admittance to *ex situ* facilities of genetic resources and to databases;
- f. Transfer to the provider of the genetic resources of knowledge and technology under fair and most favourable terms, including on concessional and preferential terms where agreed, in particular, knowledge and technology that make use of genetic resources, including biotechnology, or that are relevant to the conservation and sustainable utilization of biological diversity;
- g. Strengthening capacities for technology transfer to user developing country Parties and to Parties that are countries with economies in transition and technology development in the country of origin that provides genetic resources. Also to facilitate abilities of indigenous and local communities to conserve and sustainably use their genetic resources;
- h. Institutional capacity-building;
- i. Human and material resources to strengthen the capacities for the administration and enforcement of access regulations;
- j. Training related to genetic resources with the full participation of providing Parties, and where possible, in such Parties;

- k. Access to scientific information relevant to conservation and sustainable use of biological diversity, including biological inventories and taxonomic studies;
- l. Contributions to the local economy;
- m. Research directed towards priority needs, such as health and food security, taking into account domestic uses of genetic resources in provider countries;
- n. Institutional and professional relationships that can arise from an access and benefit-sharing agreement and subsequent collaborative activities;
- o. Food and livelihood security benefits;
- p. Social recognition;
- q. Joint ownership of relevant intellectual property rights.